Država: Velika Britanija
Jezik: angleščina
Source: HMA (Heads of Medicines Agencies)
pergolide mesilate 1.31 mg
Boehringer Ingelheim Vetmedica GmbH
QN04BC02
Tablet
Pergolide
Horses Non Food
2011-12-21
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prascend 1 mg tablets for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each tablet contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg) EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Pink, rectangular scored tablet, engraved on one side with the Boehringer Ingelheim logo and the let ters “PRD”. The tablets can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses not intended for human consumption 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equin e Cushing’s Disease). 4.3 CONTRAINDICATIONS Do not use in horses with known hypersensitivity to pergolide mesylate or other ergot derivatives. Do not use in horses less than 2 years of age. 4.4 SPECIAL WARNINGS Appropriate endocrinologic laboratory tests should be conducted as well as evaluation of clinical signs in order to establish a diagnosis of PPID. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS As the majority of cases of PPID are diagnosed in aged horses , other pathological processes are frequently present. For monitoring and frequency of testing, see section 4.9. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS This product may cause eye irritation, an irritating smell, or headache after splitting. Minimise exposure risks when splitting tablets. Tablets should not be crushed. Avoid contact with the eyes a Preberite celoten dokument